Literature DB >> 9756751

Reduction by cefodizime of the pulmonary inflammatory response induced by heat-killed Streptococcus pneumoniae in mice.

Y Bergeron1, N Ouellet, A M Deslauriers, M Simard, M Olivier, M G Bergeron.   

Abstract

It has recently become apparent that overwhelming inflammatory reactions contribute to the high mortality rate associated with pneumococcal infection in immunocompetent hosts. Cefodizime (CEF) is an antibiotic that seems to be endowed with immunomodulating properties. To investigate the influence of CEF on the pulmonary inflammatory response induced by Streptococcus pneumoniae, we infected mice with repeated intranasal inoculations of 10(7) CFU of heat-killed fluorescein isothiocyanate-labeled bacteria, which are insensitive to the killing properties of the drug. CEF downregulated but did not abolish the strong polymorphonuclear leukocyte (PMN) recruitment induced by S. pneumoniae. PMN recruitment was not primarily mediated by leukotriene B4 in this model. The drug did not interfere with intrinsic mechanisms of phagocytosis by PMNs and alveolar macrophages. CEF totally abrogated the pneumococcus-induced tumor necrosis factor alpha (TNF-alpha) and interleukin-6 (IL-6) secretion in bronchoalveolar lavage fluid. The drug also prevented IL-6 release in lung homogenates and partly inhibited TNF-alpha, but it did not interfere with IL-1alpha secretion in the lungs of infected mice. The fractional and selective downregulation of inflammatory cells and cytokines by CEF suggests cell-specific and intracellular specific mechanisms of interaction of the drug. The immunomodulatory properties of CEF may help restrain excessive inflammatory reactions, thus contributing to the reported good clinical efficacy of the drug against lower respiratory tract infections.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9756751      PMCID: PMC105879     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  55 in total

1.  Cytokine kinetics and other host factors in response to pneumococcal pulmonary infection in mice.

Authors:  Y Bergeron; N Ouellet; A M Deslauriers; M Simard; M Olivier; M G Bergeron
Journal:  Infect Immun       Date:  1998-03       Impact factor: 3.441

2.  [Effects of antibiotics on production of cytokines by human monocytes].

Authors:  S Bailly; M Fay; M A Gougerot-Pocidalo
Journal:  Pathol Biol (Paris)       Date:  1993-10

3.  Immunopharmacological activity of cefodizime in young and elderly subjects: in vitro and ex vivo studies.

Authors:  P L Meroni; F Capsoni; M O Borghi; W Barcellini; F Minonzio; A M Ongari; C Fain; C Hu; G Brambilla; C Pettenati
Journal:  Infection       Date:  1992       Impact factor: 3.553

Review 4.  In vivo activity of cefodizime.

Authors:  P M Shah; H Knothe
Journal:  Infection       Date:  1992       Impact factor: 3.553

5.  Influence of cefodizime on the reagibility of human leukocytes.

Authors:  M Limbert; H Müllner; P M Shah
Journal:  Infection       Date:  1992       Impact factor: 3.553

6.  Cefodizime, an aminothiazolyl cephalosporin. III. Therapeutic activity against experimentally induced pneumonia in mice.

Authors:  N Klesel; M Limbert; G Seibert; I Winkler; E Schrinner
Journal:  J Antibiot (Tokyo)       Date:  1984-12       Impact factor: 2.649

7.  Cefodizime, an aminothiazolyl cephalosporin. IV. Influence on the immune system.

Authors:  M Limbert; R R Bartlett; G Dickneite; N Klesel; H U Schorlemmer; G Seibert; I Winkler; E Schrinner
Journal:  J Antibiot (Tokyo)       Date:  1984-12       Impact factor: 2.649

8.  Phagocyte function and cytokine production in community acquired pneumonia.

Authors:  K Moussa; H J Michie; I A Cree; A C McCafferty; J H Winter; D P Dhillon; S Stephens; R A Brown
Journal:  Thorax       Date:  1994-02       Impact factor: 9.139

9.  Antibiotics and production of granulocyte-macrophage colony-stimulating factor by human bronchial epithelial cells in vitro. A comparison of cefodizime and ceftriaxone.

Authors:  Y Pacheco; R Hosni; E E Dagrosa; F Gormand; B Guibert; B Chabannes; M Lagarde; M Perrin-Fayolle
Journal:  Arzneimittelforschung       Date:  1994-04

10.  Heat-killed pneumococci and pneumococcal capsular polysaccharides stimulate tumor necrosis factor-alpha production by murine macrophages.

Authors:  S Q Simpson; R Singh; D E Bice
Journal:  Am J Respir Cell Mol Biol       Date:  1994-03       Impact factor: 6.914

View more
  6 in total

Review 1.  Interference of antibacterial agents with phagocyte functions: immunomodulation or "immuno-fairy tales"?

Authors:  M T Labro
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

2.  Comparison of pulmonary inflammatory and antioxidant responses to intranasal live and heat-killed Streptococcus pneumoniae in mice.

Authors:  Miroslava Dominis-Kramarić; Martina Bosnar; Zeljko Kelnerić; Ines Glojnarić; Snježana Cužić; Michael J Parnham; Vesna Eraković Haber
Journal:  Inflammation       Date:  2011-10       Impact factor: 4.092

Review 3.  Modulation of release of proinflammatory bacterial compounds by antibacterials: potential impact on course of inflammation and outcome in sepsis and meningitis.

Authors:  Roland Nau; Helmut Eiffert
Journal:  Clin Microbiol Rev       Date:  2002-01       Impact factor: 26.132

4.  Interleukin-10 gene therapy-mediated amelioration of bacterial pneumonia.

Authors:  D F Morrison; D L Foss; M P Murtaugh
Journal:  Infect Immun       Date:  2000-08       Impact factor: 3.441

5.  Influence of cefodizime on pulmonary inflammatory response to heat-killed Klebsiella pneumoniae in mice.

Authors:  Y Bergeron; A M Deslauriers; N Ouellet; M C Gauthier; M G Bergeron
Journal:  Antimicrob Agents Chemother       Date:  1999-09       Impact factor: 5.191

6.  Ceftiofur regulates LPS-induced production of cytokines and improves LPS-induced survival rate in mice.

Authors:  Xinxin Ci; Hongyu Li; Yu Song; Na An; Qinlei Yu; Fanqin Zeng; Xuming Deng
Journal:  Inflammation       Date:  2008-12       Impact factor: 4.092

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.